文献速递甲状腺疾病

靶向肿瘤缺氧抑制去分化甲状腺癌的侵袭性表型

Targeting Tumor Hypoxia Inhibits Aggressive Phenotype of Dedifferentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究利用本中心及GEO数据库转录组数据,发现缺氧评分与去分化状态、总生存期缩短、TP53突变及免疫抑制标志物升高相关;ACF和靶向HIF-1α的siRNA在体外和体内抑制甲状腺癌细胞生长并降低c-MYC和PDL1表达;缺氧评分与部分癌种免疫治疗反应相关。

要点

  • 缺氧评分与去分化状态正相关,高评分与总生存期缩短、TP53突变及免疫抑制标志物升高相关。
  • ACF和靶向HIF-1α的siRNA在体外和体内抑制甲状腺癌细胞生长,降低c-MYC和PDL1表达。
  • 缺氧评分与部分癌种免疫治疗反应相关,HIF-1α与DDTC中PDL1表达正相关。

核心结论

  • 缺氧评分是DDTC患者去分化状态、预后及由肿瘤免疫功能障碍和排斥预测的免疫治疗反应的重要指标。
  • 在DDTC临床前模型中,ACF靶向缺氧有助于减轻ATC的侵袭性表型。

研究设计与样本

  • 利用本中心和Gene Expression Omnibus(GEO)数据库的转录组数据发现并确认缺氧与甲状腺癌去分化状态、不良预后及免疫检查点的相关性。
  • 体外和体内用吖啶黄(ACF)处理未分化甲状腺癌(ATC)细胞研究靶向缺氧的效果,并分析缺氧与患者免疫治疗反应的关系。

主要发现

  • 缺氧评分与去分化状态正相关,高缺氧评分与总生存期缩短、TP53突变及免疫抑制相关标志物表达升高显著相关。
  • ACF和靶向HIF-1α的siRNA在体外和体内显著抑制甲状腺癌细胞生长和增殖,并降低ATC中c-MYC和PDL1表达。
  • HIF-1α在DDTC中与PDL1表达正相关。
  • 磷酸化蛋白质组和RNA测序数据整合分析显示,ACF的靶点通过肿瘤相关激酶与ATC中的分化基因和免疫检查点相连。
  • 缺氧评分与部分癌种的免疫治疗反应相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypoxia is commonly observed in multiple aggressive cancers. Its role remains unclear in the biology and therapy of dedifferentiated thyroid cancer (DDTC). OBJECTIVE: We aimed to elucidate hypoxia's roles in DDTC tumor biology. METHODS: We discovered and confirmed hypoxia's correlation with dedifferentiation status, poor prognoses, and immune checkpoints in thyroid cancer using transcriptome data from our center and Gene Expression Omnibus (GEO) database. Then, the effect of targeting hypoxia was investigated via treating anaplastic thyroid cancer (ATC) cells with acriflavine (ACF) in vitro and in vivo, and hypoxia was analyzed for its association with response to immunotherapy in patients. RESULTS: Hypoxia score was positively associated with dedifferentiation status, and high hypoxia score significantly correlated with reduced overall survival, TP53 mutation, and elevated expression of immunosuppression-related markers in DDTC. ACF and siRNA targeting HIF-1α significantly suppressed growth and proliferation of thyroid cancer cells in vitro and in vivo, and reduced c-MYC and PDL1 expression in ATC. HIF-1α showed a positive correlation with PDL1 expression in DDTC. Integrated analyses of phosphoproteome and RNA sequencing data revealed that ACF's target was connected with differentiation genes and immune checkpoints via tumor-related kinases in ATC. Furthermore, hypoxia score was associated with immunotherapeutic response in some cancer types. CONCLUSION: Hypoxia score serves as a significant indicator for dedifferentiation status, prognoses, and immunotherapeutic response predicted by Tumor Immune Dysfunction and Exclusion in DDTC patients. Targeting hypoxia by ACF is useful to alleviate aggressive phenotype of ATC in a preclinical model of DDTC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ma B, Wen S, Luo Y, et al. Targeting Tumor Hypoxia Inhibits Aggressive Phenotype of Dedifferentiated Thyroid Cancer. J Clin Endocrinol Metab. 2023. PMID: 36190930. doi:10.1210/clinem/dgac548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。